Sunee Sirivichayakul1, Rami Kantor2, Allison K DeLong2, Rapeeporn Wongkunya3, Suwanna Mekprasan1, Kiat Ruxrungtham4, Annette H Sohn5, Praphan Phanuphak6. 1. Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 2. Alpert Medical School, Brown University, Providence, RI, USA. 3. The Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 4. Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand The Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 5. TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand. 6. Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand The Thai Red Cross AIDS Research Centre, Bangkok, Thailand praphan.p@chula.ac.th.
Abstract
OBJECTIVES: The aim of this study was to prospectively survey transmitted drug resistance (TDR) among recently infected individuals (mostly MSM). METHODS: TDR was determined in prospective annual cohorts of recently HIV-1-infected individuals consecutively recruited from 2008 to 2010. Resistance interpretation was carried out using Stanford Database tools and the WHO surveillance drug resistance mutation list. Kruskal-Wallis and Fisher's exact tests were used to compare demographic and laboratory outcomes. RESULTS: A total of 299 subjects were enrolled, with 89% MSM. Median viral load was significantly higher in 2010 than in 2008 (P=0.004). Of the 284 analysable reverse transcriptase/protease sequences, TDR to any drug was found in 14/284 (4.9%); 4.0% in 2008, 5.9% in 2009 and 5.3% in 2010, with an increasing trend of TDR to NRTIs and NNRTIs from 2008 to 2010 (P=0.07). Good correlation was found between our data and the WHO threshold surveillance method. Only rilpivirine had significantly higher (P<0.05) predicted resistance in 2010 than in 2008 and 2009. CONCLUSIONS: A trend towards an increase in TDR in Thailand where the major epidemic is among MSM was observed, but did not reach the WHO-defined high-level threshold (>15%). Attention to prevent the development and spread of drug resistance is needed.
OBJECTIVES: The aim of this study was to prospectively survey transmitted drug resistance (TDR) among recently infected individuals (mostly MSM). METHODS: TDR was determined in prospective annual cohorts of recently HIV-1-infected individuals consecutively recruited from 2008 to 2010. Resistance interpretation was carried out using Stanford Database tools and the WHO surveillance drug resistance mutation list. Kruskal-Wallis and Fisher's exact tests were used to compare demographic and laboratory outcomes. RESULTS: A total of 299 subjects were enrolled, with 89% MSM. Median viral load was significantly higher in 2010 than in 2008 (P=0.004). Of the 284 analysable reverse transcriptase/protease sequences, TDR to any drug was found in 14/284 (4.9%); 4.0% in 2008, 5.9% in 2009 and 5.3% in 2010, with an increasing trend of TDR to NRTIs and NNRTIs from 2008 to 2010 (P=0.07). Good correlation was found between our data and the WHO threshold surveillance method. Only rilpivirine had significantly higher (P<0.05) predicted resistance in 2010 than in 2008 and 2009. CONCLUSIONS: A trend towards an increase in TDR in Thailand where the major epidemic is among MSM was observed, but did not reach the WHO-defined high-level threshold (>15%). Attention to prevent the development and spread of drug resistance is needed.
Authors: Lisa Ross; Michael L Lim; Qiming Liao; Brian Wine; Allan E Rodriguez; Winkler Weinberg; Mark Shaefer Journal: HIV Clin Trials Date: 2007 Jan-Feb
Authors: B G Weniger; K Limpakarnjanarat; K Ungchusak; S Thanprasertsuk; K Choopanya; S Vanichseni; T Uneklabh; P Thongcharoen; C Wasi Journal: AIDS Date: 1991 Impact factor: 4.177
Authors: Paul E Sax; Runa Islam; Rochelle P Walensky; Elena Losina; Milton C Weinstein; Sue J Goldie; Sara N Sadownik; Kenneth A Freedberg Journal: Clin Infect Dis Date: 2005-09-23 Impact factor: 9.079
Authors: Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: Martin S Hirsch; Huldrych F Günthard; Jonathan M Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Scott M Hammer; Victoria A Johnson; Daniel R Kuritzkes; John W Mellors; Deenan Pillay; Patrick G Yeni; Donna M Jacobsen; Douglas D Richman Journal: Clin Infect Dis Date: 2008-07-15 Impact factor: 9.079
Authors: Patricia Cane; Ian Chrystie; David Dunn; Barry Evans; Anna Maria Geretti; Hannah Green; Andrew Phillips; Deenan Pillay; Kholoud Porter; Anton Pozniak; Caroline Sabin; Erasmus Smit; Jonathan Weber; Mark Zuckerman Journal: BMJ Date: 2005-11-18